|
Research InterestsAssociate Professor Kate Moore | | (Position Details) | | Phone 02 9113 2054 | | Email | | Qualifications MB BS Syd, MD Liv, FRCOG, FRANZCOG, CU |
| | | School/Unit |
| School of Women's and Children's Health | |
| | Broad Research Areas | |
|
Gynaecology
Pharmacology
Evidence Based Medicine
| |
| | | | Specific Research Keywords | |
| Incontinence
Urinary
| |
| | | | Research Interests | |
|
In the field of gynaecology, the aetiology and treatment of urge incontinence (detrusor overactivity) is the primary research interest. Definition of objective outcome measures, including the costs of treatment, are also important research interests.
| |
| | | | Teaching Interests | |
| Undergraduate teaching involves face-to-face instruction of Phase 3 students regarding incontinence, in the Pelvic Floor Unit at St George Hospital. The Unit also regularly provides clinical research projects for ILP students. Postgraduate teaching includes training of Urogynaecology research fellows and PhD/MD candidates. | |
| | | | Society Memberships & Professional Activities | |
| Member of:
International Continence Society
International Urogynaecology Association
Continence Foundation of Australia
Serve as:
Member of WHO International Consensus on Incontinence
Previous Member of Expert Advisory Committee to Minister for Health and Ageing on the National Continence Management Strategy
Associate editor of International Urogynaecology Journal
Associate editor of Continence Journal of Australia | |
| | | | Funding Sources | |
| NHMRC: Neuropeptides in the Human Bladder
Commonwealth Government (competitive Tender - Establishing an Economic framework for analysis of the Cost of Incontinence)
Pfizer Peer Reviewed Scientific Research Grant
International Urogynaecology Association (IUGA) Research Fellowship | |
| | | | Key works/Publications | |
| Peer Reviewed Publications
1. Moore KH, Hay D, Imrie A, Watson A, Goldstein M. Oxybutynin Hydrochloride 3 mg in the treatment of women with idiopathic detrusor instability. Brit J Urol. 1990; 66: 479-485.
2. Moore KH, Sutherst JR. Response to treatment of detrusor instability in relation to psychoneurotic status. Brit J Urol. 1990; 66: 486-490.
3. Moore KH, Richmond DH, Sutherst JR. Urinary acidity in relation to detrusor instability. Neurourol & Urodyn 1990; 9: 331-332.
4. Moore KH, Sill PR. Domiciliary fetal monitoring in a district maternity unit. Aust NZ J Obstets & Gynaecol 1990; 30: 36-40.
5. Skehan M, Moore KH, Richmond DH. The auditory stimulus of running water; its effect on urethral pressure. Neurourol & Urodyn 1990; 9: 351-353.
6. Moore KH, Richmond DH, Sutherst JR, Imrie AI, Hutton JL. Crouching over the toilet seat: Prevalence among British gynaecological outpatients and its effect upon micturition. Brit J Obstets & Gynaecol 1991; 98: 569-572.
7. Moore KH, Richmond DH, Parys BT. Sex distribution of adult idiopathic detrusor instability in relation to childhood bedwetting. Brit J Urol 1991; 68: 479-482.
8. Moore KH, Vaillant C, Nameth J, Richmond D, Sutherst J. Vasoactive intestinal polypeptide in refractory detrusor instability. Neurourol & Urodyn 1991; 10: 330-331.
9. Moore KH, Nickson P, Richmond DH, Sutherst JR, Manasse PR, & Helliwell TR. Detrusor mast cells in refractory idiopathic instability. Brit J Urol 1992; 70: 17-21.
10. Moore KH, Gilpin SA, Dixon JS, Richmond DH & Sutherst JR. An increase of presumptive sensory nerves of the urinary bladder in idiopathic detrusor instability. Brit J Urol 1992; 70: 370-372.
11. Moore KH, Richmond DH, Sutherst JR, Manasse PR. "One-shot" biofeedback in relation to psychoneurotic status and treatment response in detrusor instability. Neurourol & Urodyn 1992; 11: 365-366.
12. Moore KH, Richmond DH, Sutherst JR, Manasse P. Is severe "wetness" associated with severe "madness" in detrusor instability? Neurourol & Urodyn 1992; 11: 460-461.
13. Zeng XP, Moore KH, Burcher E. Characterization of Tachykinin NK-2 receptors in human urinary bladder. J Urol 1995; 153: 1688-1692.
14. Burcher E, Zeng XP, Farnsworth RH, Moore KH. Functional characterization of tachykinin NK-2 receptors in child urinary bladder. Neurourol & Urodyn 1995; 14: 546-548.
15. Moore KH. Detrusor Instability in Women. Its significance for continence therapists. Invited Review, Brit J Physiotherapy. 1996; 82: 52-57.
16. Bower WF, Moore KH, Shepherd RB, Adams R. The epidemiology of childhood enuresis in Australia. Brit J Urol 1996; 78: 602-606.
17. Millard RJ, Moore KH. Urinary incontinence: the cinderella subject. Invited Editorial. Med J Aust 1996; 165: 124-125.
18. Bower WF, Moore KH. Frequency volume chart data from 322 incontinent children. Brit J Urol 1997; 80: 658-662.
19. Smet P, Moore KH, Jonavicius J. Distribution and colocalisation of calcitonin gene-related peptide, tachykinins, and vasoactive intestinal peptide in normal and idiopathic unstable human urinary bladder. Lab Invest 1997; 77: 37-49.
20. Moore KH, Foote AJ, Siva S, King J, Burton G. The use of the bladder neck support prosthesis in combined genuine stress incontinence and detrusor instability. Aust NZ J Obstets & Gynaecol 1997; 37: 440-445.
21. Bower WF, Moore KH, Adams RD, Shepherd RB. A urodynamic study of surface neuromodulation versus sham in detrusor instability and sensory urgency. J Urol 1998; 106: 2133-2136.
22. Moore KH, Foote AJ, Burton G, King J. An open study of the bladder neck support prosthesis in genuine stress incontinence. Brit J Obstets & Gynaecol 1999; 106: 42-49
23. Dowell CJ, Bryant CM, Moore KH, Simons AM. Calculation of the direct costs of urinary incontinence: the DBICI, a new test instrument. Brit J Urol 1999; 83: 596-606.
24. Moore KH. Current controversies in the diagnosis, aetiology and management of detrusor instability. Critical Reviews in Physical and Rehabilitation Medicine. (Invited Review). 1999; 11: 35-61.
25. Millard R, Tuttle J, Moore K, Susset J, Clarke B, Dwyer P, Davis BE. Clinical efficacy and safety of Tolterodine compared to placebo in detrusor overactivity. J Urol 1999; 161: 1551-1555.
26. Simons A, Cragg S, Moore KH. The sub-optimal accuracy of the bladderscan: reliability against a known volume, using a measure of agreement. Neurourol & Urodyn 1999; 18: 307-308.
27. Moore KH, Simons A, Dowell C, Bryant C, Prashar S. Efficacy and user acceptibility of the urethral occlusive device in women with urinary incontinence. J Urol 1999; 162: 464-468.
28. Burcher E, Strigas J, Zeng XP, Shang F, Millard RJ, Moore KH. Autoradiographic localization of tackykinin and calcitonin gene-related peptide receptors in adult urinary bladder. J Urol 1999; 162: 464-468.
29. Werkstrom V, Lam DSH, Farnsworth RH, Awar N, Burcher E, Moore KH. In vitro contractile responses of detrusor to carbachol and neurokinin A, in children with recurrent urinary tract infection or day wetting. Brit J Urol 2000; 85: 319-325.
30. Prashar S, Simons A, Bryant C, Dowell C, Moore K. Attitudes to vaginal/urethral touching and device placement in women with urinary incontinence. Int Urogynaecol J 2000; 11: 4-8.
31. Moore KH, Simons A, Mukerjee C, Lynch W. Relative incidence of detrusor instability and bacterial cystitis found on the urodynamic test day. Brit J of Urol 2000; 85: 786-792.
32. Lam DSH, Dias LS, Moore KH, Burcher E. Angiotensin II in child urinary bladder: functional and autoradiographic studies. Brit J Urol 2000; 86: 494-501.
33. Simons AM, Dowell CJ, Bryant CM, Prashar S, Moore KH.. Use of the Dowell Bryant incontinence cost index as a post-treatment outcome measure. Neurourol & Urodyn.2001; 20: 85-93.
34. Simons AM, Yoong WC, Buckland S, Moore KH. Inadequate repeatability of the one hour pad test: the need for a new incontinence outcome measure. Brit J Obstets & Gynaecol 2001; 108: 315-319.
35. Moore KH. The costs of urinary incontinence: human suffering and financial drain. Med J Aust 2001; 174: 436-437. (Invited Review)
36. O’Sullivan R, Dunkley P, Allen W, Moore KH. Urodynamic monitoring during extracorporeal magnetic stimulation for patients with idiopathic detrusor instability; with an open clinical trial. Neurourol & Urodyn 2001; 20: 413-416.
37. Moore KH, Ray F, Barden JA. Loss of purinergic P2X3 and P2X5 receptor innervation in human detrusor from adults with urge incontinence. J Neuroscience. 2001; 21:RC166:1-6.
38. Bower WF, Moore KH, Adams RD. A pilot study of the home application of transcutaneous neuromodulation in children with urgency or urge incontinence. J Urol 2001; 166: 2420-2422.
39. Clausen JA, Lynch WJ, Aslan P, Moore KH. Alterations in the distribution of GAP-43/P75NTR in urinary bladder from human urge syndrome/OAB. Neurourol & Urodyn 2001; 20: 399-401.
40. Bower WF, Moore KH, Adams RD. A novel clinical evaluation of childhood incontinence and urinary urgency. J Urol 2001; 166: 2411-2415.
41. Moore KH, Lam DSH, Lynch W, Burcher E. The role of tachykinin NK-2 receptors in non-cholinergic contractility of normal and unstable human urinary bladder. Peptides. 2002; 23:1155-1160.
42. Moore KH, Louey M, Ip V, Swinfield J, Ho MP. The cost of a continence service in the acute hospital – is it being “counted”? Neurourol & Urodyn 2002; 21: 345-347.
43. Dietz HP, Moore KH, Steensma AB. Antepartum pelvic organ mobility is associated with delivery mode. Aust NZ J Obstets & Gynaecol 2003; 43: 70-74.
44. Herbison P, Hay-Smith J, Ellis G, Moore KH. Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: systematic review. Brit Med J 2003; 326: 841-847. Also published as BMJ USA 3(June 2003):319-22.
45. Qi JC, Li L, Li Yong, Moore KH, Madigan MC, Katsoulotos G, Krilis SA. An antibody raised against in vitro-derived human mast cells identifies mature mast cells and a population of cells that are Fc&RI+, Tryptase -, and Chymase- in a variety of human tissues. Journal of Histochemistry & Cytochemistry 2003; 51:643-653.
46. Green P, Smoker I, Ho MT, Moore KH. Urinary incontinence in sub-acute care - a retrospective data analysis. Med. J Aust 2003; 178: 550-553.
47. Karantanis E, O’Sullivan R, Moore KH. The 24-hour pad test in continent women and men: normal values and cyclical alterations. Brit J Obstet & Gynae 2003; 110: 567-571.
48. Blackwell AL, Moore KH. Does detrusor overactivity ever cease? Repeat urodynamic testing at 1 to 9 years. Neurourol & Urodyn 2003; 22:462-463.
49. Moore KH, O’Sullivan RJ, Simons A, Prashar S, Anderson P, Louey M. Randomized controlled trial of nurse continence advisor therapy versus standard urogynaecology regime for conservative incontinence treatment: Efficacy, costs and two year follow up. Brit.J Obstet & Gynae 2003; 110: 649-657.
50. Mansfield FJ, Mitchelson FJ, Moore KH, Burcher E. Muscarinic receptor subtypes in the human colon: lack of evidence for atypical subtypes. Eur J Pharmacol 2003; 482: 101-109.
51. Ray FR, Moore KH, Hansen MA, Barden JA. Loss of purinergic P2X receptor innervation in human detrusor and subepithelium from adults with sensory urgency. Cell and Tissue Res 2003; 314: 351-359.
52. O’Sullivan R, Simons A, Prashar S, Anderson P, Louey A, Moore KH. Is objective cure of mild undifferentiated incontinence more readily achieved than that of moderate incontinence? Costs and two year outcome. Int J Urogynaecol. 2003; 14(3):193-198.
53. Morris A, Moore KH. The Contiform incontinence device - efficacy and patient acceptability. Int. J Urogynaecol 2003; 14: 412-417.
54. Morris AR, Westbrook JI, Moore KH. Idiopathic detrusor overactivity in women - A 5-10 year longitudinal study of outcomes. Neurourol & Urodyn 2003; 22:460-462.
55. Millard RJ, Moore KH, Rencken, Yalcin I, Bump RC. Duloxetine vs placebo in the treatment of stress urinary incontinence: a four continent randomized clinical trial. Brit J Urol Int. 2004; 93: 311-318.
56. Blackwell AL, Yoong W, Moore KH . Criterion validity, test retest reliability and sensitivity to change of the St George Urinary Incontinence Score. Brit J Urol Int 2004; 93: 331-335.
57. Karantanis E, Fynes M, Moore KH, Stanton SL. Comparison of the ICIQ-SF and 24-hour pad test with other measures for evaluating the severity of urodynamic stress incontinence. Int.Urogynecol J 2004; 15:111-116.
58. Deans CL, Morris AR, O’Sullivan R, Moore KH. Voiding difficulty and other adverse events after tension free vaginal tape. Aust NZ Cont J. 2004; 10:34-41.
59. Morris AR, Mullan G, Roscioli T, Buckley MF, Moore KH. A genetic linkage study of detrusor overactivity. Neurourol & Urodyn 2004; 23: 404-406.
60. O’Sullivan R, Karantanis E, Stevermuer TL, Allen W, Moore KH. Definition of mild, moderate and severe incontinence on the 24-hour pad test. Brit J Obstet & Gynae 2004; 111: 859-862.
61. Moore KH. Duloxetine: a new approach for treating stress urinary incontinence. Int J Gynecol Obstet 86 Suppl 1 2004, S53-S62. (Invited Review)
62. Moore KH. Pelvic Floor Dysfunction: how best to treat? (Invited Review) RANZCOG Obs & Gynae. 2004; 6:195-196.
63. Morris A, Ho MT, Walsh J, Gonski G, Lapsley H, Moore KH. Costs of managing urinary and faecal incontinence in a subacute care facility. A “bottom up” approach. Neurourol & Urodyn 2005; 24:56-62.
64. Karantanis E, Allen W, Stevermuer TL, Simons AM, O’Sullivan R, Moore KH. The repeatability of the 24-hour pad test. Int Urogynecol J 2005; 16:63-68.
65. Mansfield K, Liu L, Mitchelson FJ, Moore KH, Burcher E. Muscarinic receptor subtypes in human bladder detrusor and mucosa , studied by radioligand binding and quantitative competitive RT-PCR: changes in ageing. Brit J Pharmacol 2005; 144 (8): 1089-1099.
66. Schofield EC, Clausen JA, Burcher E, Moore KH. GAP-43 immunoreactivity in subepithelial and detrusor muscle nerve fibres in females with refractory idiopathic detrusor overactivity. Neurourol & Urodyn. 2005; 24:325-333.
67. Kuteesa W, Moore KH. Anticholinergic drugs for overactive bladder. (Invited review) Australian Prescriber 2006; 29 (1):22-24.
68. Ho M, Kuteesa W, Short A, Eastwood A, Moore KH. Personal and treatment costs of childbirth related incontinence. Neurourol & Urodyn. 2006; 25:513-514.
69. Kuteesa W, Moore KH. Overactive bladder in women: advances in management. (Invited review) Medicine Today 2006; 7(4):44-53.
70. Sadananda P, Lazzaro VA, Moore KH, Burcher E, Mansfield KJ. Urothelial cells isolated from urine of female subjects release ATP in response to acid. Neurourol & Urodyn. 2006; 25:559-560.
71. Karantanis E, Wang K, Fynes M, Moore KH. 24-hour pad test: a comparison of normal ranges between two countries and according to the type of pad used. Neurourol & Urodyn. 2006; 25:608-609.
72. Woodman, JR. Moore KH, Thornton M, Burns H, King D. Anal incontinence after transanal versus transvaginal repair of rectocoele: matched pair cohort analysis. A&NZ Continence Journal 2007; 13:40-45.
73. Mansfield, K, Liu L, Moore KH, Vaux KJ, Millard RJ, Burcher E. Molecular characterization of M2 and M3 muscarinic receptor expression in bladder from women with refractory idiopathic detrusor overactivity. BJU Int. 2007; 99:1433-1438.
74. Chua WC, Liu L, Mansfield, KJ, Vaux KJ, Moore KH, Millard RJ, Burcher E. Age-related changes of P2X1 receptor mRNA in the bladder detrusor from men with and without bladder outlet obstruction. Experimental Gerontology 2007; 42:686-692.
75. Foote AJ, Moore KH. The cost of urogynaecological treatments: which are more cost effective. ANZJO&G 2007; 47:240-246.
76. Morris A, O’Sullivan R, Dunkley P, Moore KH. Extra corporeal magnetic stimulation in female detrusor overactivity; simultaneous cystometry testing and a randomized sham controlled trial. European Urology 2007, 52:876-883.
77. Steers WD, Herschorn S, Kreder KJ, Moore K, Strohbehn K, Yalcin I, Bump RC for the Duloxetine OAB Study Group. Duloxetine compared with placebo for treating women with symptoms of overactive bladder. Br J Urol Int 2007; 100:337-345
78. Moore KH, Sarma S. The changing face of detrusor overactivity therapy in Australia (invited review). A&NZ Continence Journal 2007, 13: 90-94.
79. Allen WA, Leek H, Izurieta A, Moore KH. Update: the “Contiform” intravaginal device in four sizes for treatment of stress incontinence. Int J Urogynaecol. 2008; 19:757-761.
80. Morris AR, Westbrook JI, Moore KH. A longitudinal study over 5 to 10 years of clinical outcomes in women with idiopathic detrusor instability. BJOG 2008; 115:239-246.
81. Ho, T. Eastwood A, Kuteesa W, Short A, Moore KH. Incontinence after childbearing: Longitudinal analysis of direct costs of conservative and surgical therapy. Int. J Urogynaecol. Submitted April 2007.
82. Woodman JR, Sarma S, Karantanis E, Moore KH. A Longitudinal study of asymptomatic rectocoele. Eur. J. Obs. Gynae. Submitted May 2009.
83. Cheng Y, Allan W, Walsh C, Mansfield K, Burcher E, Moore KH. ATP Release during cystometry in women with detrusor overactivity and painful bladder syndrome: Contribution to “urgency”? ICS 2009. Accepted May 2009.
84. Sarma S, Thakkar K, Hayes W, Karantanis E, Hawthorn G, Moore KH. The Development of an Incontinence Treatment Motivation Questionnaire for patients undergoing Pelvic Floor Physiotherapy in the treatment of Stress Incontinence. Int. J Urogynaecol. Submitted ………
85. Sarma S, Ying, T, Moore KH. Long term vaginal ring pessary use: discontinuation rates and adverse events. BJOG. Submitted June 2009.
2. Chapters
1. Moore KH. “In the 1970s”. Women in the Medical Society. Invited chapter. Ann Jervie Sefton, Nicholas Cheng, Ian G. Thong. eds. The Centenary Book of the Sydney University Medical Society. 1992; 190-193.
2. Moore KH. "Prolapse and Urinary Incontinence" Leader L, Bennett MJ, Wong F. eds. in Handbook of Obstetrics and Gynaecology, 4th Ed., 1996; 391-409.
3. Versi E, Defever M, Hu TW, Kobelt G, Moore K, Subak L, Zinner N. “Socio-economic Considerations in Urinary Incontinence”. Report of World Health Organisation, Editors: Abrams P, Khoury S, Wein A. 1998; 22: 869-929, Health Publications Ltd., Plymouth.
4. Moore KH. “Conservative Therapy for Incontinence”. Invited Chapter, Monograph on Urinary Incontinence, Clinical Obstetrics and Gynaecology series. 2000; 14: 251-289, Balliere’s Clinical Obstetrics and Gynaecology
5. Hu TW, Moore KH, Subak L, Versi E, Wagner T, Zinner N. “The economics of incontinence”. Report of World Health Organisation, Editors: Abrams P, Cardozo L, Koury S, Wein A. 2001; 14: 965-983, Health Publications Ltd., Plymouth.
6. Hu TW, Wagner TH, Hawthorne G, Moore KH, Subak L. “Economics of Incontinence”. Report of World Health Organisation, Editors: Abrams P, Cardozo L, Koury S, Wein A. 2005:2:75-95. Health Publications Ltd., Plymouth.
7. A Morris, KH Moore. “Extracorporeal magnetic stimulation”. In textbook of Pelvic Floor Rehabilitation. Editors: Schussler B, Moore KH, Baessler K, Norton P, Stanton SL. 2008. 196-200. Springer-Verlag London Limited.
8. J Hay Smith, KH Moore. “Evidence for the Effectiveness of Pelvic Floor Muscle Training in the Treatment and Antenatal Prevention of Female Urinary Incontinence”: In textbook of Pelvic Floor Rehabilitation.. Editors: Schussler B, Moore KH, Baessler K, Norton P, Stanton SL. 2008. 228-234. Springer-Verlag London Limited.
9. P Chiarelli, KH Moore. “Exercise Feedback, and Biofeedback”. In textbook of Pelvic Floor Rehabilitation. Editors: Schussler B, Moore KH, Baessler K, Norton P, Stanton SL. 2008. 184-189. Springer-Verlag London Limited.
10. KH Moore, E Karantanis. “Outcomes measures in pelvic floor rehabilitation”. In textbook of Pelvic Floor Rehabilitation.. Editors: Schussler B, Moore KH, Baessler K, Norton P, Stanton SL. 2008. 162-174. Springer-Verlag London Limited.
11. Moore KH, Hu TW, Subak L, Wagner TH, Duetekom, M. “Economics of Urinary & Faecal Incontinence, and Prolapse”. Report of World Health Organisation, Editors: Abrams P, Cardozo L, Koury S, Wein A. 2009:1687-1712. Health Publications Ltd., Plymouth.
3. Books
3A. Monographs
1. Moore, KH. “Urogynecology in Evidence Based Clinical Practice”. Textbook. Editor Moore, KH. 2006. Invited to author this monograph by Springer-Verlag, London.
Review: Burton G, RANZCOG O&G Magazine, 2007, 9 (1):62.
Review: Bower E, A&NZ Continence Journal, 2007, 13(1):22-23.
2. Moore KH, Ho MT, Lapsey H, Brown I, Smoker Irenie, Morris A, O’Sullivan R, Green J, Gonski P, Poulos C, Walsh J, Prince W, Gibson-Jones M, Wells L, Shiaxates, Dowell C, Louey M, Swinfield, Huckel D. Report to Commonwealth Department of Health and Ageing. “Development of a Framework for Economic and Cost Evaluation for Continence Conditions”. 2006
3. Thomas, S, Nay R, Moore KH, Fonda D, Hawthorne G. “Continence Outcomes Measurement Suite”. Report to Commonwealth Department of Health and Ageing. 2006.
3B. Books Edited
1. Moore KH. “Sensible Women”. Kate Moore ed. Australian Women in Medicine. Sydney Women’s Health Students Group. 1978; 55 pages.
2. Arnold PC Series Editor, Moore KH Consultant Editor for the volume entitled: “Urinary Incontinence in Women”. The Australian Medical Association, Dorling Kindersley, Sydney. 2000. 88 pages.
3. Bassler K, Schussler B, Burgio KL, Moore KH, Norton PA, Stanton S (Eds). “Pelvic Floor Re-education, Principles and Practice”. Springer Verlag, London (Invited to co-edit the second edition of this text) ISBN: 978-1-85233-968-5. June 2008. | |
| | | | Further Information | |
| www.pelvicfloorunit.com.au | |
Profile last updated: 12/11/2009 Need to update your profile? Login to your profile with your Staff ID, prefixed by a lower case "s" or "z" (eg s1234567 or z1234567), and UniPass to update your profile. If you have any problems please send an email to .
|
|